Oligonucleotide modulation of protein kinase C
AssigneeIsis Pharmaceuticals, Inc.
InventorsC. Frank Bennett, Nicholas Dean
Life of this patent
Estimating the term…
Abstract
Compositions and methods are provided for the treatment and diagnosis of diseases associated with protein kinase C. Oligonucleotides are provided which are specifically hybridizable with nucleic acid encoding PKC. Oligonucleotides specifically hybridizable with a translation initiation site, 5'-untranslated region or 3'-untranslated region are provided. Oligonucleotides specifically hybridizable with a particular PKC isozyme or set of isozymes are also provided. Methods of treating animals suffering from disease amenable to therapeutic intervention by modulating protein kinase C expression with an oligonucleotide specifically hybridizable with RNA or DNA corresponding to PKC are disclosed.
Claims21
An isolated and purified oligonucleotide consisting of a nucleotide sequence selected from the group consisting of SEQ ID NO:
- 2 and SEQ ID NO:
- 5.
An isolated and purified oligonucleotide consisting of SEQ ID NO:
- 2, wherein said oligonucleotide hybridizes to DNA or RNA encoding human protein kinase C and reduces human protein kinase C expression.
An isolated and purified oligonucleotide consisting of SEQ ID NO:
- 3, wherein said oligonucleotide hybridizes to DNA or RNA encoding human protein kinase C and reduces human protein kinase C expression, wherein the IC.sub.50 is 1 .mu.M or less.
An isolated and purified oligonucleotide consisting of SEQ ID NO:
- 5, wherein said oligonucleotide hybridizes to DNA or RNA encoding human protein kinase C and reduces human protein kinase C expression.
Dependencies are inferred from the claim text.